New drug approach shows promise in treating metabolic liver diseases
December 18, 2024 / Metabolic Liver Disease Treatment / ATGL Enzyme Inhibition / MASLD and MASH Therapies / Liver Fat Reduction
MedUni Vienna researchers demonstrated that pharmacological inhibition of ATGL enzyme improves liver health by reducing fat, inflammation, and fibrosis in metabolic liver diseases. This breakthrough could lead to targeted therapies for MASLD and MASH, advancing treatment options.
Subjective walking speed can serve as a simple predictor of metabolic health in obese individuals
December 19, 2024 / Walking Speed / Obesity / Metabolic Health / Diabetes Risk Reduction / Hypertension Prevention Tools
A study revealed that subjective walking speed predicts metabolic health in obese individuals. Faster self-reported walking speeds correlated with reduced risks of diabetes, hypertension, and dyslipidemia, making it a practical, cost-effective tool for public health assessments.d
Strategies to Manage Metabolic Health During the Holidays
December 19, 2024 / Weight Gain Prevention / Metabolic Health Interventions / Childhood Health Solutions / Weight Control
A systematic review highlights the effectiveness of holiday interventions—nutrition education, physical activity, and psychological support—in reducing weight gain among children and adults. Targeted strategies during high-risk periods can improve metabolic health and prevent obesity-related complications.
Combating Obesity: Reducing The Risk Of Metabolic Diseases In India
December 23, 2024 / Obesity / Metabolic Disease Prevention / NAFLD and Obesity Link
Obesity in India drives metabolic diseases like diabetes and NAFLD, with societal misconceptions delaying interventions. Early action, awareness, lifestyle changes, and advanced treatments like bariatric surgery are essential to combating this growing health crisis effectively.
A New Way To Treat Obesity? Scientists Discover Brain Molecules That Control Food Cravings
December 22, 2024 / Obesity Treatment Breakthrough / Brain Molecules and Food Cravings
CRCHUM researchers found that inhibiting the enzyme ABHD6 in specific brain regions reduced obesity in mice by curbing food cravings and boosting physical activity, without anxiety or depression. This discovery offers potential for novel obesity treatments.
The role of phytochemicals in combating metabolic diseases
December 19, 2024 / Phytochemicals / Metabolic Health / Plant-based Disease Prevention / Natural Treatment for Diabetes
Phytochemicals, abundant in plant-based foods, show promise in preventing and managing metabolic diseases by modulating inflammation, gut microbiota, and oxidative stress. Studies highlight their potential in improving glucose metabolism, vascular health, and reducing disease complications.
MetaVia reports positive DA-1241 trial results for MASH
December 18, 2024 / DA-1241 Clinical Trials / MASH Treatment / Agonist Therapy / Liver Health / Glucose Control / Drug Development
MetaVia’s Phase 2a trial for DA-1241 shows promising results in treating MASH, with significant ALT reductions, improved liver health, and glucose control. The GPR119 agonist also demonstrated safety, paving the way for FDA discussions in 2025.
New drug approach shows promise in treating metabolic liver diseases
December 18, 2024 / ATGL Emzyme Inhibition / MASLD Treatment Breakthrough / Liver Health Imprevement Strategies / Metabolic Liver Disease Research / MASH
MedUni Vienna’s study found that inhibiting ATGL enzyme significantly improved liver health in metabolic liver diseases by reducing fat, inflammation, and fibrosis. These findings, demonstrated in preclinical and human models, mark a step toward targeted MASLD and MASH therapies.
Viking Therapeutics Stock Slides After Merck Strikes GLP-1 Deal With Chinese Biopharma, Retail Unperturbed
December 18, 2024 / Wiking Therapeutics / Obesity Treatment / GLP-1 Drug Market Competition
Viking Therapeutics’ stock dropped 9% following Merck’s GLP-1 deal with Hansoh Pharma, raising competition concerns in the obesity drug market. Despite this, Viking’s GLP-1 candidate VK2735 shows strong promise, retaining bullish investor sentiment.
Contributor: Treating Obesity by Breaking the GLP-1 Pattern
December 20, 2024 / GLP-1 Drug Limitations / Obesity / Duodenal Mucosal Resurfacing / Metabolic Health Solutions
GLP-1 drugs provide temporary symptom relief for obesity and T2D but fail to address root causes. Emerging therapies like duodenal mucosal resurfacing (DMR) aim to reset gut health, offering potential long-term solutions for metabolic diseases.
Overactive Cells Linked to Type 2 Diabetes
December 18, 2024 / Overactive Chemoreceptors Diabetes / Type 2 Diabetes / Metabolic Disorder
University of Missouri researchers identified overactive carotid chemoreceptors as contributors to cardiovascular and metabolic issues in type 2 diabetes. While hyperoxia reduced chemoreceptor activity, it didn’t improve glucose tolerance, redirecting focus to alternative therapeutic approaches.
Prediction of metabolic subphenotypes of type 2 diabetes via continuous glucose monitoring and machine learning
December 23, 2024 / Continuous Glucose Monitoring / Type 2 Diabetes / Machine Learning in Diabetes / Insulin
Continuous glucose monitoring (CGM) combined with machine learning accurately predicts metabolic subphenotypes in early type 2 diabetes and prediabetes. This scalable method enables personalized prevention and treatment by identifying insulin resistance, β-cell dysfunction, and other metabolic abnormalities.
Dual screening for liver fibrosis and retinopathy in type 2 diabetes
December 17, 2024 / Dual Screening T2D Patients / Liver Fibrosis Detection / MASLD in Type 2 Diabetes / Retina Scanning and VCTE
Simultaneous retina scanning and VCTE screening in type 2 diabetes (T2D) patients effectively identified liver fibrosis and MASLD, with a high acceptance rate. This dual approach could enhance early detection, despite some false positives requiring careful evaluation.
Evotec SE Announces First Projects for LAB eN² Drug Discovery Accelerator With Novo Nordisk
December 17, 2024 / Drug Discovery / Novo Nordisk Evotec Collaboration / Cardiometabolic Disease Research / Drug Discovery
Evotec and Novo Nordisk’s LAB eN² accelerator has launched its first three cardiometabolic projects from Boston University, Harvard, and Joslin Diabetes Center. These initiatives target chronic kidney disease, metabolic syndrome, and type 1 diabetes, aiming to translate innovative academic research into therapeutic candidates.
Intermittent Fasting Shows Promise for Weight loss and improved Metabolic Health in new research
December 21, 2024 / Intermittent Fasting Benefits / Time-restricted Eating / Weight Loss / Metabolic Health / NAFLD
An umbrella review confirms intermittent fasting, particularly time-restricted eating (TRE), as an effective approach for weight loss and metabolic health. Benefits include improved insulin sensitivity, reduced body fat, and enhanced liver health in overweight and obese adults.